BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain
- Conditions
- Drug/Agent Toxicity by Tissue/OrganCognitive/Functional EffectsBrain and Central Nervous System TumorsBreast CancerPsychosocial Effects of Cancer and Its Treatment
- Interventions
- Registration Number
- NCT00397501
- Lead Sponsor
- OHSU Knight Cancer Institute
- Brief Summary
RATIONALE: Osmotic blood-brain barrier disruption uses certain drugs, such as mannitol, to open the blood vessels around the brain and allow tumor-killing substances to be carried directly to the brain. Drugs used in chemotherapy, such as methotrexate and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Trastuzumab may also help methotrexate and carboplatin work better by making tumor cells more sensitive to the drugs. Giving osmotic blood-brain barrier disruption together with methotrexate, carboplatin, and trastuzumab may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of carboplatin when given together with methotrexate and trastuzumab after mannitol in treating women with breast cancer that has spread to the brain.
- Detailed Description
OBJECTIVES:
Primary
* Determine the safety and toxicity associated with blood-brain barrier disruption comprising transfemoral mannitol followed by methotrexate and carboplatin with or without trastuzumab (Herceptin®) in women with brain metastasis secondary to breast cancer. (Phase I)
* Determine if overall survival exceeds 5 months in patients with Human Epidermal growth factor Receptor 2(HER2)-positive or HER2-negative disease treated with this regimen. (Phase II)
Secondary
* Determine the overall survival of these patients.
* Compare the event-free and overall survival, steroid use, response rates, and time to best response in patients with HER2-positive vs HER2-negative disease.
* Assess the quality of life of patients treated with this regimen.
* Assess the neuropsychological effects of this treatment regimen in these patients.
* Determine cerebrospinal fluid levels of trastuzumab before and after blood-brain barrier disruption.
OUTLINE: This is a multicenter, phase I, pilot, dose-finding study of carboplatin followed by a phase II, open-label study.
* Phase I: Patients undergo osmotic blood-brain barrier disruption (BBBD) comprising mannitol by transfemoral catheterization followed by methotrexate intra-arterially (IA) over 10 minutes and carboplatin IA over 10 minutes on days 1 and 2. Patients also receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after each dose of carboplatin; leucovorin calcium IV or orally every 6 hours on days 3-9; and pegfilgrastim subcutaneously (SC) on day 4 or filgrastim (G-CSF) SC beginning on day 4 and continuing until blood counts recover (7-10 days). Patients with HER-2 positive disease receive trastuzumab (Herceptin®) IV over 90 minutes within 48 hours prior to BBBD and then weekly for 3 weeks (between BBBD therapy sessions). Treatment repeats every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive decreasing doses of carboplatin and/or methotrexate if the proposed dose is not well tolerated. Dose-limiting toxicity is defined as grade IV hematologic toxicity with delay in subsequent treatment courses for 4 weeks OR grade III/IV nonhematologic toxicity without recovery in 14 days during the course of treatment.
* Phase II: Patients undergo BBBD as in phase I and receive carboplatin and methotrexate at the doses determined in phase I. Patients also receive sodium thiosulfate, leucovorin calcium, and pegfilgrastim or G-CSF as in phase I. Patients with HER2-positive disease also receive trastuzumab as in phase I.
Neuropsychological assessment is performed at baseline, every 6 months during treatment, every 6 months for 1 year, and then annually thereafter. Quality of life is assessed at baseline, every 3 months during treatment, at the completion of study treatment, every 6 months for 1 year, and then annually thereafter.
After completion of study therapy, patients are followed periodically.
PROJECTED ACCRUAL: A total of 78 patients will be accrued for this study.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- Female
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description HER-2 positive subjects methotrexate HER-2 positive subjects treated with trastuzumab HER-2 negative subjects carboplatin HER-2 negative subjects not treated with trastuzumab HER-2 positive subjects sodium thiosulfate HER-2 positive subjects treated with trastuzumab HER-2 negative subjects methotrexate HER-2 negative subjects not treated with trastuzumab HER-2 negative subjects sodium thiosulfate HER-2 negative subjects not treated with trastuzumab HER-2 positive subjects trastuzumab HER-2 positive subjects treated with trastuzumab HER-2 positive subjects carboplatin HER-2 positive subjects treated with trastuzumab
- Primary Outcome Measures
Name Time Method Overall survival exceeding 5 months in patients with Human Epidermal growth factor Receptor 2(HER2)-negative disease 1 year after initiation of treatment Overall survival exceeding 5 months in patients with HER2-positive disease 1 year after initiation of treatment
- Secondary Outcome Measures
Name Time Method Time to best response 5 years Quality of life 5 years Progression-free survival 5 years Complete response rate 5 years Overall survival 5 years after intitiation of treatment